The Types taxonomy classifies Next Generation Cancer Diagnostics into liquid biopsy, tissue‑based molecular profiling, imaging‑augmented genomics, and multi‑omics platforms. Liquid biopsy extracts circulating tumor DNA, RNA, or exosomes from blood, accounting for roughly 40 % of the market; its rapid turnaround and minimally invasive nature fuel adoption in both screening and longitudinal monitoring. Tissue‑based molecular profiling remains the benchmark for definitive diagnosis, contributing about 30 % as next‑generation sequencing panels expand to cover larger gene sets and gain reimbursement traction. Imaging‑augmented genomics integrates radiomic signatures with molecular data, representing an emerging niche of ~15 % that benefits from AI‑driven analytics and hybrid imaging‑genomics trials. Multi‑omics platforms combine genomics, transcriptomics, proteomics, and metabolomics to deliver comprehensive tumor characterisation, currently holding ~15 % of revenue but projected to accelerate as data‑integration pipelines mature. Regulatory agencies have begun issuing separate guidance for each type, resulting in differentiated approval timelines, reimbursement pathways, and pricing power that reinforce the distinct market contributions of each segment. Each type adds distinct value—liquid biopsy drives volume through repeat testing, tissue profiling sustains high‑margin services, imaging‑genomics opens new clinical pathways, and multi‑omics expands the analytical envelope—thereby collectively shaping the market taxonomy and influencing total addressable market calculations.
